Foster City, CA, United States of America

Junfa Fan

USPTO Granted Patents = 31 (Patent Applications = 6)

CIPO Patents = 5

EPO Patents = 9 (Patent Applications = 11)

Average Co-Inventor Count = 10.7

ph-index = 7

Forward Citations = 174(Granted Patents)

Location History:

Foster City, CA (US) (2014 - 2020)
Palo Alto, CA (US) (2017 - 2024)

Company Filing History:

Sunesis Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2014-2024

Loading Chart...

31 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12054484 - Substituted tetrahydropyrans as CCR2 modulators (2024-08-06),

2. 11945805 - Inhibitors of CXCR2 (2024-04-02),

3. 11884654 - Substituted anilines as CCR(4) antagonists (2024-01-30),

4. 11834452 - CXCR7 antagonists (2023-12-05),

5. 11820759 - Modulators of chemokine receptors (2023-11-21),

6. 11142521 - Substituted anilines as CCR(4) antagonists (2021-10-12),

7. 11059825 - CXCR7 antagonists (2021-07-13),

8. 11040960 - Inhibitors of CXCR2 (2021-06-22),

9. 10988464 - Modulators of chemokine receptors (2021-04-27),

10. 10596163 - Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides (2020-03-24),

11. 10577374 - Bruton's tyrosine kinase inhibitors (2020-03-03),

12. 10464934 - Substituted tetrahydropyrans as CCR2 modulators (2019-11-05),

13. 10407417 - Substituted anilines as CCR(4) antagonists (2019-09-10),

14. 10370363 - Inhibitors of CXCR2 (2019-08-06),

15. 10336736 - Modulators of chemokine receptors (2019-07-02),

Title: Innovations and Contributions of Junfa Fan in Pharmaceutical Research

Introduction: Junfa Fan, a prolific inventor based in Foster City, CA, has made significant strides in the field of pharmaceutical science. With an impressive portfolio of 31 patents, his work primarily focuses on the development of novel compounds that serve as modulators and inhibitors for various receptors involved in critical medical conditions.

Latest Patents: Among Junfa Fan's latest contributions to the field are two notable patents. The first, titled "Substituted Tetrahydropyrans as CCR2 Modulators," presents a series of compounds that act as modulators of the CCR2 receptor. These compounds, characterized by the general formula (Ia1′), show promise in pharmaceutical applications for treating diseases associated with the pathological activation of CCR2 receptors. The second patent, titled "Inhibitors of CXCR2," introduces compounds that effectively inhibit the CXCR2 receptor, contributing vital innovations to therapeutic strategies.

Career Highlights: Over the course of his career, Junfa Fan has been associated with several notable companies in the pharmaceutical sector, including Chemocentryx, Inc. and Sunesis Pharmaceuticals, Inc. His expertise in developing innovative compounds has not only enriched his personal career but has also advanced the capabilities of the companies he has been affiliated with.

Collaborations: Collaboration has played a crucial role in Junfa Fan's success. He has worked alongside accomplished colleagues such as Jeffrey P. McMahon and Penglie Zhang, further enhancing the impact of his research through shared knowledge and collaborative innovation.

Conclusion: Junfa Fan stands out as a leading figure in pharmaceutical invention, with a comprehensive portfolio that underscores his dedication to developing novel therapeutic solutions. His ongoing contributions through various patents pave the way for advancements in treating diseases linked to critical receptors, highlighting the crucial intersection of innovation and healthcare.

This text is generated by artificial intelligence and may not be accurate.